Davern Capital Partners, LP — 13F Holdings & Portfolio
CIK 2003147 · latest 13F-HR filed 2026-05-14
Davern Capital Partners, LP manages $364.5M in 13F-reported U.S. long-equity assets across 17 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are PFE (12.28%), REGN (9.50%), INSM (8.19%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 4 new positions, exited 1, added to 6, and trimmed 6.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$364.5M
Long-equity book
17
Distinct positions
2026-03-31
Filed 2026-05-14
+4 / −1 / ↑6 / ↓6
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ELI LILLY & CO$16.2M +181.1%
- NATERA INC$10.8M +59.8%
- IONIS PHARMACEUTICALS INC$10.2M +54.0%
- MINERALYS THERAPEUTICS INC$4.5M +58.5%
- ABIVAX SA$2.2M +33.0%
Top Trims
- BIONTECH SE-$8.2M -23.3%
- ROYALTY PHARMA PLC-$7.5M -23.2%
- PFIZER INC-$6.1M -12.0%
- REGENERON PHARMACEUTICALS-$5.8M -14.5%
- ARGENX SE-$4.4M -14.7%
New Positions
- INSMED INC$29.9M
- GENERATE BIOMEDICINES INC$7.4M
- PROCEPT BIOROBOTICS CORP$6.5M
- STRUCTURE THERAPEUTICS INC$6.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PFIZER INC | PFE | 717081103 | $44.8M | 12.28% | 1,593,942 | SH |
| 2 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $34.6M | 9.50% | 44,800 | SH |
| 3 | INSMED INC | INSM | 457669307 | $29.9M | 8.19% | 182,562 | SH |
| 4 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $29.1M | 7.97% | 386,903 | SH |
| 5 | NATERA INC | NTRA | 632307104 | $28.8M | 7.90% | 143,966 | SH |
| 6 | BIONTECH SE | BNTX | 09075V102 | $27.1M | 7.44% | 305,055 | SH |
| 7 | ARGENX SE | ARGX | 04016X101 | $25.6M | 7.02% | 35,045 | SH |
| 8 | ELI LILLY & CO | LLY | 532457108 | $25.1M | 6.88% | 27,279 | SH |
| 9 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $24.9M | 6.84% | 520,009 | SH |
| 10 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $24.2M | 6.64% | 873,398 | SH |
| 11 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $23.8M | 6.52% | 1,314,748 | SH |
| 12 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $12.1M | 3.32% | 447,153 | SH |
| 13 | ABIVAX SA | ABVX | 00370M103 | $8.7M | 2.39% | 78,125 | SH |
| 14 | GENERATE BIOMEDICINES INC | GENB | 370920100 | $7.4M | 2.03% | 591,800 | SH |
| 15 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $6.5M | 1.79% | 261,200 | SH |
| 16 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $6.1M | 1.67% | 126,461 | SH |
| 17 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $5.9M | 1.62% | 302,457 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $364.5M | 17 | 0000905148-26-002267 |
| 2025-12-31 | 2026-02-13 | $309.3M | 14 | 0000905148-26-000704 |